Skip to main content
SpringerLink
Log in
Book cover

Vaccine Adjuvants pp 15–27Cite as

Preclinical Development of AS04

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 626))

Abstract

Recent knowledge on vaccine-induced immunity led to the development of vaccine Adjuvant Systems specially designed and adapted to vaccine needs. AS04 is such a tailored Adjuvant System developed by GlaxoSmithKline Biologicals. This chapter focuses on the methods that were used during the preclinical evaluation of AS04. AS04 consists of the combination of aluminum salts and 3′-O-deacylated monophosphoryl lipid A (MPL), a detoxified lipid A derivative with retained immunostimulatory capa- city. MPL also induces considerably less pro-inflammatory cytokines, as compared to the parent LPS molecule. Preclinical evaluation of AS04 allowed the determination of the optimal size of MPL particles. The added value of MPL in AS04-based formulations was evidenced by higher vaccine-elicited antibody responses, as well as the induction of higher levels of memory B cells, as compared to aluminum alone formulations. Preclinical evaluation demonstrated the relevance of using AS04 in situations where high and long-lasting antibody levels are needed. This represents the basis for the successful application of AS04 in vaccines against hepatitis B virus and human papillomavirus.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Takeda, K., Akira, S. (2005) Toll-like receptors in innate immunity. Int Immunol 17(1), 1–14.

    Article  PubMed  CAS  Google Scholar 

  2. Beutler, B., Jiang, Z., Georgel, P., et al. (2006) Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu Rev Immunol 24, 353–389.

    Article  PubMed  CAS  Google Scholar 

  3. McKee, A. S., Munks, M. W., Marrack, P. (2007) How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27(5), 687–690.

    Article  PubMed  CAS  Google Scholar 

  4. Glenny, A. T., Buttlem, G. A. H., Stevens, M. F. (1931) Rate of disappearance of diphtheria toxoid injected into rabbits and guinea pigs: toxoid precipitated with alum. J Pathol 34, 267–275.

    Article  CAS  Google Scholar 

  5. Ramon, G. (1926) Procédés pour accroître la production des antitoxines. Ann Inst Pasteur 40, 1–10.

    Google Scholar 

  6. Garçon, N., Van Mechelen, M., Wettendorff, M. (2006) Development and evaluation of AS04, a novel and improved immunological adjuvant system containing MPL and aluminium salt, in (Schijns V., O’Hagan D., eds.) Immunopotentiators in Modern Vaccines. Elsevier Academic Press, London, pp 161–177.

    Chapter  Google Scholar 

  7. Giannini, S. L., Hanon, E., Moris, P., et al. (2006) Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24(33–34), 5937–5949.

    Article  PubMed  CAS  Google Scholar 

  8. Myers, K. R., Truchot, A. T., Word, J., Hudson, Y., Ulrich, J. T. (1990) A critical determinant of lipid A endotoxic activity, in (Nowotny A., Spitzer J. J., Ziegler E. J., eds.) Cellular and Molecular Aspects of Endotoxin Reactions. Elsevier Science Publishing Co., New York, pp 145–156.

    Google Scholar 

  9. Johnson, D. A., Keegan, D. S., Sowell, C. G., et al. (1999) 3-O-Deacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities. J Med Chem 42(22), 4640–4649.

    Article  PubMed  CAS  Google Scholar 

  10. Hirschfeld, M., Ma, Y., Weis, J. H., Vogel, S. N., Weis, J. J. (2000) Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J Immunol 165(2), 618–622.

    PubMed  CAS  Google Scholar 

  11. Tapping, R. I., Akashi, S., Miyake, K., Godowski, P. J., Tobias, P. S. (2000) Toll-like receptor 4, but not Toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J Immunol 165(10), 5780–5787.

    PubMed  CAS  Google Scholar 

  12. Iwanaga, S., Morita, T., Harada, T., et al. (1978) Chromogenic substrates for horseshoe crab clotting enzyme. Its application for the assay of bacterial endotoxins. Haemostasis 7(2–3), 183–188.

    PubMed  CAS  Google Scholar 

  13. Nakamura, S., Morita, T., Iwanaga, S., Niwa, M., Takahashi, K. (1977) A sensitive substrate for the clotting enzyme in horseshoe crab hemocytes. J Biochem 81(5), 1567–1569.

    PubMed  CAS  Google Scholar 

  14. European Pharmacopea. (1971). Test for pyrogens, Vol. 11. Published under the direction of the Council of Europe, Maisonneuve SA, Sainte-Ruffine, France, pp 58–60.

    Google Scholar 

  15. The European Medicines Agency (EMEA). (2005) Committee for medicinal products for human use (CHMP). Guideline on adjuvants in vaccines for human use. (EMEA/CHMP/VEG/134716/2004) (http://www.emea.europa.eu/pdfs/human/vwp/13471604en.pdf).

  16. World Health Organization. (2005) Guidelines on nonclinical evaluation of vaccines. WHO Technical Report Series No. 927, Annex 1, pp 31–63 (http://www.who.int/biologicals/publications/trs/areas/vaccines/nonclinical_evaluation/en/).

  17. Bernasconi, N. L., Traggiai, E., Lanzavecchia, A. (2002) Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298(5601), 2199–2202.

    Article  PubMed  CAS  Google Scholar 

  18. Harper, D. M., Franco, E. L., Wheeler, C., et al. (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364(9447), 1757–1765.

    Article  PubMed  CAS  Google Scholar 

  19. Harper, D., Gall, S., Naud, P., et al. (2008) Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long-term follow up through 6.4 years in women vaccinated with Cervarix™ (GSK’s HPV 16/18 AS04 candidate vaccine). Gynecol Oncol 109(1), 158–159.

    Article  Google Scholar 

  20. Kong, N. C. T., Beran, J., Kee, S. A., et al. (2008) A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 73(7), 856–862.

    Article  PubMed  CAS  Google Scholar 

  21. Beran, J. (2008) Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 8(2), 235–247.

    Article  PubMed  CAS  Google Scholar 

  22. Kool, M., Pétrilli, V., De Smedt, T., Rolaz, A., Hammad, H., van Nimwegen, M., Bergen, I. M., Castillo, R., Lambrecht, B. N., Tschopp, J. (2008) Cutting edge: Alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 181(6), 3755–3759, Sep 15.

    Google Scholar 

Download references

Acknowledgments

The author is thankful to Ulrike Krause and Pascal Cadot for their assistance in the preparation of the chapter. FENDrix and Cervarix are trade marks of the GlaxoSmithKline group of companies.

Author information

Authors and Affiliations

  1. Global Adjuvant Center for Vaccine, GlaxoSmithKline Biologicals, Wavre, Belgium

    Nathalie Garçon

Authors
  1. Nathalie Garçon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nathalie Garçon .

Editor information

Editors and Affiliations

  1. Dept. Cardio & Vascular Sciences, St. George's University of London, Cranmer Terrace, London, SW17 0RE, United Kingdom

    Gwyn Davies

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Garçon, N. (2010). Preclinical Development of AS04. In: Davies, G. (eds) Vaccine Adjuvants. Methods in Molecular Biology, vol 626. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-585-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-585-9_2

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-584-2

  • Online ISBN: 978-1-60761-585-9

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation